FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy

FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy

Submitted by admin on October 23, 2018 - 11:00pm
Source: 
CP Wire
News Tags: 
Omeros
OMS721
stem cells
thrombotic microangiopathy
Headline: 
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
snippet: 

Omeros Corporation (NASDAQ:OMER) announced on 10/23/18 that OMS721 has received orphan drug designation from the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). 

Do Not Allow Advertisers to Use My Personal information